Does Aetna (CVS Health) Cover Crestor (Rosuvastatin)?

What Aetna's 2026 Documents Actually Show

Aetna publishes multiple drug lists, not one universal formulary. The 2026 Standard Control Choice exclusion list names Crestor among drugs not covered and lists atorvastatin, ezetimibe-simvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin as preferred options. [1]

The 2026 Advanced Control exclusion list makes the same Crestor listing and includes generic rosuvastatin among the preferred options. [2] These documents support a precise statement about those plan designs. They do not prove that every Aetna plan excludes brand Crestor, assigns it the same tier, charges the same copay, or uses the same prior-authorization steps.

Aetna's plan pages explicitly warn that drug lists and utilization-management rules can change and that tier information shown for a sample plan may not match an individual member's plan. They direct members to sign in for personalized coverage and cost information. [3]

Brand Crestor vs. Generic Rosuvastatin

Crestor and approved generic rosuvastatin contain the same active ingredient. The current U.S. label lists rosuvastatin as an HMG-CoA reductase inhibitor for lowering LDL-C in specified populations and reducing major cardiovascular events in adults at increased risk. [4]

When a plan excludes the brand but covers generic rosuvastatin, the generic is usually the most direct coverage route. A request for brand Crestor is stronger when it identifies a patient-specific reason the covered generic or other preferred options are not clinically appropriate. A general preference for the brand is not the same as evidence of medical necessity.

The prior page stated that most Aetna plans place Crestor on Tier 3 or Tier 4. The published 2026 exclusion lists show why that wording was unreliable: in two prominent plan designs, the brand is excluded rather than merely placed on a high tier.

How to Check the Exact Aetna Plan

Use this sequence before submitting a prior-authorization request:

1. Sign in to the Aetna member site and search both “Crestor” and “rosuvastatin.”
2. Confirm the exact plan name and benefit year; do not substitute a similarly named public formulary.
3. Record whether the result says covered, excluded, prior authorization, step therapy, quantity limit, or a specific tier.
4. If the member site and pharmacy claim disagree, call the number on the member ID card and ask which drug-list document controls the claim.
5. Ask for the applicable exception or coverage-determination form and keep the denial code or letter.

This avoids treating an employer's custom benefit, a commercial plan, and Medicare Part D as if they had the same rules.

Prior Authorization, Medical Exception, or Appeal?

These are related but different requests.

• A prior authorization asks the plan to confirm that stated coverage criteria are met.
• A medical or formulary exception asks the plan to cover a drug that is excluded or waive a utilization-management rule.
• An appeal asks the plan to reconsider an adverse decision already issued.

Aetna's pharmacy FAQ says a prescriber may need to provide a diagnosis, lab results, or other medical-record information for prior authorization. It directs members whose request is denied to consider an alternative or follow the appeal steps in the denial letter. [5] The ACC/AHA cholesterol guideline can support the clinical goal, but the plan document still controls the coverage route. [6]

For a published Aetna plan that excludes Crestor, calling the problem “a routine PA” may send the request down the wrong path. The plan may instead require a medical exception. Aetna's 2026 plan pages provide a medical-exception route for certain non-covered drugs and instruct members to use their plan resources for the controlling details. [3]

What Evidence Makes an Exception More Specific

A useful submission ties each claim to the member's record:

Rosuvastatin 20 mg and 40 mg are high-intensity statin doses under the ACC/AHA cholesterol guideline; atorvastatin 40 mg and 80 mg are also high-intensity options. [6] That clinical classification can support the treatment goal, but it does not by itself prove that brand Crestor is necessary instead of generic rosuvastatin.

Appeal and Decision Timelines Depend on Plan Type

The previous page mixed Medicare Part D deadlines with commercial Aetna appeals. The correct timeline depends on the benefit.

For Medicare Part D, CMS says a formulary exception can request coverage of a non-formulary drug or waiver of prior authorization, step therapy, or a quantity limit. Once the plan receives the prescriber's supporting statement, it must issue a decision within 72 hours for a standard request or 24 hours for an expedited request. [7]

For Aetna commercial pharmacy exception appeals, Aetna's public FAQ says an appeal can take up to 15 business days; a permitted second-level appeal can also take up to 15 business days. [5] State law and the member's plan can change the process. The denial letter is the controlling source for filing method and deadline.

Do not assume that the Medicare 24/72-hour coverage-determination clock applies to every Aetna commercial appeal, or that every commercial plan has the same number of appeal levels.

Step Therapy Is Not Universal Across Aetna

Aetna explains that some plans may require trying one or more generic drugs before a brand is covered, but the company also notes that utilization programs are not available in all service areas and plan documents control. [3]

The public Crestor exclusion lists do not prove that every affected member must complete one identical step sequence. In some plans the issue is formulary exclusion, in others it may be step therapy or prior authorization, and in still others the brand may be covered. State-specific override rights can also differ. The exact denial reason must be identified before choosing the remedy. The CMS exception framework applies to Part D, not automatically to commercial benefits. [7]

The Clinical Evidence for Rosuvastatin

The coverage question should remain separate from whether rosuvastatin is an evidence-based medicine. In JUPITER, 17,802 participants with elevated high-sensitivity C-reactive protein and LDL-C below 130 mg/dL were randomized to rosuvastatin 20 mg or placebo. Rosuvastatin reduced the primary cardiovascular endpoint, with a hazard ratio of 0.56. [8]

Current labeling and cholesterol guidelines support rosuvastatin for appropriate lipid-lowering and cardiovascular-risk indications. [4, 6] Neither source says a payer must cover the brand when an equivalent generic is available, and neither validates fabricated Aetna tier or price claims.

Costs, Coupons, and Savings Cards

The prior page quoted fixed copays, cash prices, list prices, and accumulator behavior without current plan-specific evidence. Those figures have been removed.

Out-of-pocket cost can change with plan design, deductible status, pharmacy, quantity, benefit year, and eligibility for a manufacturer program. The member portal, pharmacy claim, and current manufacturer terms are the relevant sources on the day of purchase. A savings card should not be described as available or applicable unless its current eligibility terms are checked for that member.